Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | AKT2 | P31751 | 2/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15040971 | 1.00 | MAOB (0.38) | MAOBMAOAAKT1AKT2AKT3 | |
| SCHEMBL3044171 | 0.81 | ACHE (0.42) | MAOBMAOAMEN1MAPTKMT2A | |
| SCHEMBL303097 | 0.81 | ACHE (0.42) | MAOBMAOAMEN1MAPTKMT2A | |
| SCHEMBL301682 | 0.81 | ACHE (0.42) | MAOBMAOAMEN1MAPTKMT2A | |
| SCHEMBL29365202 | 0.81 | ACHE (0.42) | MAOBMAOAMEN1MAPTKMT2A | |
| SCHEMBL11871293 | 0.81 | HPGD (0.44) | MAOBMAOAHPGDMEN1MAPT | |
| SCHEMBL16746500 | 0.81 | HPGD (0.44) | MAOBMAOAHPGDMEN1MAPT | |
| SCHEMBL11871299 | 0.81 | HPGD (0.44) | MAOBMAOAHPGDMEN1MAPT | |
| SCHEMBL15040995 | 0.76 | ACHE (0.39) | MAOBMAOAMEN1MAPTKMT2A | |
| SCHEMBL12977461 | 0.70 | RARB (0.36) | HPGDMEN1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9757378-B2 | Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation | UNIVERSITE DE MONTREAL (CA) | 2017-09-12 | — | — | US | disclosed |
| US-9593062-B2 | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer | DEUTSCHLAND KREBSFORSCHUNGSZENTRUM (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20140294860-A1 | MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2014-10-02 | — | — | US | disclosed |
| EP-2023910-B1 | AH RECEPTOR ANTAGONISTS | SYMRISE AG (DE) | 2013-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAOB 4813/4885MAOA 4790/4885AKT1 3153/4885 |
| US-20140294860-A1 | MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER | AHR, ARNT, HMOX1 | MAOB 323/4885MAOA 269/4885AKT1 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.